Triple-negative (ER-, PR-, HER2-negative) breast cancers make up the majority of this subgroup [41], [61] and are generally unresponsive to standard treatments, i.e. tamoxifen, aromatase inhibitors and herceptin. This evidence concerns the gene CYP19A1 and breast cancer.